Traditional views of the inflammasome highlight the assembly of pre-existing core components shortly after infection or tissue damage. Emerging work, however, suggests that the inflammasome machinery is also subject to 'tunable' or inducible signals that might accelerate its autocatalytic properties and dictate where inflammasome assembly takes place in the cell. Many of these signals operate downstream of interferon receptors to elicit inflammasome regulators, including a new family of interferoninduced GTPases called 'guanylate-binding proteins' (GBPs). Here we investigate the critical roles of interferon-induced GBPs in directing inflammasome subtype-specific responses and their consequences for cell-autonomous immunity to a wide variety of microbial pathogens. We discuss emerging mechanisms of action and the potential effect of these GBPs on predisposition to sepsis and other infectious or inflammatory diseases.
Evolutionary 'arms races' drive host-specific adaptations to microbial pathogens 1 . In vertebrates, they often promote expansive and increasingly complex immunological repertoires that bear limited resemblance to their ancestral precursors and that can be acquired through horizontal gene transfer 1, 2 . Two prime examples of this are the interferon family of cytokines and the caspase-1 inflammasome machinery 3, 4 . Interferons arose in basal chordates ~500 million years ago 3 , while the caspase-1 inflammasome has extant functional relatives in jawed fish but not amphibians 5 , which suggests it originated after the teleost-tetrapod split ~450 million years ago. Both interferons and inflammasomes act co-operatively in marshaling protective immunity to infection in higher species such as mammals. Interferons not only regulate the expression of many core inflammasome proteins but also direct their spatial assembly through physical and functional interactions with other products of interferon-stimulated genes (ISGs) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . These interactions control both the specificity and the amplitude of inflammasome activation. Thus, this alliance has important consequences for mammalian host defense and the inflammatory sequelae that often accompany infectious insult.
In this Perspective, we discuss emerging evidence on how interferons affect inflammasome-mediated immunity and focus on a new family of interferon-induced GTPases (guanosine 5′-triphosphatases), the 65-to 73-kilodalton (kDa) guanylate-binding proteins (GBPs) 3, 24 . Interferon-induced GBPs help customize inflammasome responses to a variety of microbial signatures. They also provide a conceptual framework wherein inflammasome activation can be viewed as a dynamic process empowered by interferon-induced transcriptional signals and subject to post-translational regulation by previously unknown interferon-induced host-defense proteins.
The inflammasome as a 'tunable' molecular machine Inflammasomes integrate environmental signals through a series of conformational 'switches' to assemble multiprotein complexes. These signals include pathogen-associated molecular patterns (PAMPs) and endogenous danger-associated molecular patterns detected largely in the cytosol of macrophages, monocytes, splenic and plasmacytoid dendritic cells, T cells and B cells, neutrophils, keratinocytes and inflamed endothelium 4, 9, 10, 16, [25] [26] [27] [28] . Complex assembly leads to caspase-1-dependent cleavage of pro-interleukin 1β (pro-IL-1β) and pro-IL-18 to their mature exported forms as part of the canonical inflammasome pathway. A second non-canonical cascade enlists caspase-11 (caspase-4 and caspase-5 in humans) as an upstream intracellular receptor for lipopolysaccharide (LPS) that mobilizes immunity specifically to Gram-negative bacteria 11, 15, [29] [30] [31] [32] . Both pathways induce a lytic form of programmed cell death called 'pyroptosis' that can eliminate infected target cells via a mechanism genetically distinct from cytokine release 13, 15, [27] [28] [29] [30] [31] 33, 34 .
The formation of an inflammasome complex is itself a tunable and amplifying process in which large (1-to 2-µm) 'prion-like' foci typically incorporate sensor proteins that belong to either the NLR family or the PYHIN family, several of which are interferon inducible, along with multiple copies of the adaptor ASC ('apoptosis-associated, speck-like protein containing a caspase-recruitment domain (CARD)') 35, 36 . ASC in turn recruits procaspase-1, which becomes autoactivated via proximity-induced nucleation to cleave its cytokine substrates as part of an 'all-or-none' processing mechanism 4, 25, 26, 33 . Crystallographic and cryo-electron microscopy studies have suggested that sensors and adaptors exist as auto-inhibited monomers Interferon-induced guanylate-binding proteins in inflammasome activation and host defense
Interferon-inducible signals for inflammasome priming and assembly Interferon-induced signals promote canonical and non-canonical inflammasome-mediated immunity to a diverse array of microbial pathogens. TLR4-TRIF-IRF3-induced IFN-β boosts canonical AIM2-dependent secretion of IL-1β in response to Francisella tularenis or Listeria monocytogenes 6, 7 and helps to control caspase-11-dependent pyroptosis by Gram-negative bacteria 11, 34 . The interferon-induced transcription factors STAT1 and IRF1 likewise elicit AIM2-dependent cytokine and cell-death responses to Francisella novicida 22, 23 . In addition, the type II interferon IFN-γ enhances AIM2-induced release of IL-1β and NLRP3-dependent cleavage of pro-IL-18 during infection with herpes simplex virus type 1 or Chlamydia muridarum 16, 20 . The upregulated expression of NLRP3, ASC and procaspase-1 by IFN-γ can help lower the PAMP-triggered activation threshold by ~5-to 20-fold due to increased levels of core proteins 12, 17, 18, 20 . This synergism is observed for the NLRP3 inflammasome across multiple settings 12, 13, 17, 18, 20 . In contrast, NLRP3 responses to alum, monosodium urate and silica crystals are largely unaffected by IFN-γ treatment 12, 18, 22, 23, 42 and inhibited by type I interferons 42 . Thus, sterile crystalline agents are handled differently by host cells than soluble ligands are, and this difference might be further sensitized by tumor-necrosis factor rather than interferons 43 .
IFN-γ has also emerged as a potent activator of caspase-11-dependent defense against cytosolic pathogens, such as Burkholderia thailandensis in macrophages and challenged mice 19 . Protection can be ascribed partly to IFN-γ-induced expression of procaspase-11 during infection with Gram-negative bacteria 15, 17, 18 that is reliant on STAT1 signaling but not IRF1 signaling 44, 45 . Priming with the type II interferon IFN-γ also heightens caspase-11 expression and responses to LPS transfected directly into the cytosol 15, 17, 21 . Such potentiation often approaches that seen for autocrine IFN-β signaling, which suggests that the products of ISGs induced by IFN-γ might eventually prove as important as those governed by IFN-β for inflammasome responses to cytosolic LPS. Future studies will determine their respective contributions.
Two IFN-γ-induced proteins that singly affect inflammasomemediated immunity are the transcriptional activator IFI16 and the kinase PKR. IFI16 encounters Kaposi sarcoma-associated herpesvirus in the nucleus before translocating to the cytosol for assembly with ASC and procaspase-1, which demonstrates that ligand detection and inflammasome activation can be spatially segregated 10 . PKR engages multiple subtypes of inflammasomes in the cytosol (NLRP1, NLRP3, NAIP-NLRC4 and AIM2) 46 , although this breadth of activity has been questioned 47 . Chemical proteomics have confirmed its role at least for the NLRP1 inflammasome, in which 7DG (7-desacetoxy-6,7-dehydrogedunin), a drug that targets PKR, interferes with anthrax toxin-induced cell death 48 . Other PKR-related activities need to be confirmed by further analysis.
Collectively, there is mounting evidence that interferons control inflammasome responses to bacterial and viral pathogens. Which ISG-encoded proteins direct these activities, however, still remains a largely open question for the field. Part of the answer has now been furnished by the discovery of a family of IFN-γ-induced 65-to 73-kDa GBPs 3, 24 . The GBPs exhibit inflammasome subtype-specific functions in both canonical pathways and non-canonical pathways.
Discovery of GBPs as inflammasome regulators
We identified mammalian GBPs as direct inflammasome regulators despite their lack of any functional or structural similarities to NLRs, PYHIN proteins or inflammatory caspases 12, 24 . This unexpected discovery arose from genome-wide evolutionary screens designed to uncover clues about the potent antibacterial functions of GBPs 49 . Published studies using in silico identification of interferon-induced inflammasome proteins such as AIM2 had relied on a binary logic for which the functional criteria were known, such as the detection of DNA leading to the secretion of IL-1β. Pfam protein family sequence databases 'seeded' with inflammasome pyrin domain sequences thus retrieved proteins that also harbored the HIN200 DNA-binding motif 39, 40 . Domain-accretion approaches, however, were unsuitable for the analysis of mammalian GBPs because their globular N-terminal GTPase domains and C-terminal helical domains offered few insights into their potential host-defense activities 24, 49 . We thus opted for a different strategy, asking instead whether the interdomain profiles of ancestral GBPs could reveal hidden immunological connections still operative in mammals, even if those domains were now distributed on seemingly unrelated proteins through evolutionary divergence 12 . In this way, probing the multidomain configuration of GBPs in lower organisms might suggest functional relationships in higher species that were otherwise imperceptible because they act over large protein distances 24 .
That unorthodox approach yielded striking results. Screening by hidden Markov modeling identified 574 GBP-related sequences (including those encoding atlastins; root hair-defective 3; GTPase, very large interferon inducible; and GBP families) from 91 taxa spanning vertebrates, protists, plants and algae 12 . Further filtering produced 193 authentic GBPs harboring both N-terminal GTPase domains and C-terminal helical domains; the GTPase domains shared 60-64% similarity with those of human GBPs 12 . Prominent among these were GBPs from jawed fish with inflammasome-related CARDs like those in ASC and NLRP1 from multiple species, including humans (Fig. 1) . Crystallization efforts have shown that these similarities extend to the atomic level; the zebrafish IGBP1 (zGBP3) CARD contains a six-helix bundle fold almost identical to that of npg p e r s p e c t I v e nature immunology VOLUME 17 NUMBER 5 MAY 2016 human NLRP1 or ASC 50 (Fig. 1) . In addition to CARDs, we also discovered that protochordates (for example, Brachiostomata) have GBPs fused to death effector domains. These domains share homology with human caspase-8 and the FADD death domain, which would suggest a potential role in inflammasome-mediated cell death as well. Evolutionary 'mining' of ancient GBP-like sequences thus identified modular links with host inflammasome and pyroptosis pathways. It also opened the possibility of functional interplay between the GBPs and inflammasome-related proteins in higher species such as mammals ( Fig. 1) .
GBPs in canonical inflammasome activation
Initial experimental efforts focused on the contribution made by each human and mouse GBP to canonical inflammasome activation 12 . So far, seven intact human GBP-encoding genes (GBP1-GBP7) on chromosome 1q22.2 and eleven mouse GBP-encoding loci (Gbp1-Gbp11) distributed across two clusters on chromosomes 3H1 and 5E5 have been identified 49, [51] [52] [53] (Fig. 2) . GBPs form part of a 47-member interferon-inducible GTPase superfamily comprising the 21-to 47-kDa immunity-related GTPases (IRGs), 72-to 82-kDa myxoma-resistance proteins, and ~200-to 285-kDa 'GTPase, very large interferon inducible' proteins in both humans and mice 24 (Fig. 2) . Most of these GTPases undergo nucleotide-dependent self-assembly, and several of them target pathogen-containing vacuoles (PCVs), as first shown for the GMS-and GKS-containing IRGs 54, 55 . These proteins are potently induced by IFN-γ, with the exception of myxoma-resistance proteins, which instead respond to type I or type III interferons 24 . For this reason, inflammasome loss-of-function screens began by priming macrophages with IFN-γ and LPS to ensure each GBP was fully expressed for family-wide analysis.
Silencing of genes via small interfering RNA identified two orthologs, human GBP5 and its mouse counterpart (67% amino acid identity), needed for activation of the NLRP3 inflammasome. The generation of Gbp5 −/− mice confirmed they have interferondependent defects in activation of the NLRP3 inflammasome. Here, Gbp5 −/− bone marrow-derived macrophages (BMMs) showed impaired IFN-γ-induced processing of caspase-1, IL-1β and IL-18 in response to ATP given along with one of three bacterial cell wall products (LPS, muramyl dipeptide, or γ-D-glutamyl-meso-diaminopimelic acid). Gbp5 −/− BMMs were not defective for activation of the NAIP-NLRC4 inflammasome by flagellin or of the AIM2 inflammasome by double-stranded DNA 12 (Fig. 3) . Subsequent work has verified that the dependence of NLRP3 on GBPs is more conspicuous in IFN-γ-activated cells 20 than in non-activated cells 22, 23 , presumably because IFN-γ induces robust GBP expression 49, 52 . Notably, GBP5-mediated defects are independent of host species (human or mouse) or strain background (C57BL/6J, C57BL6N or BALB/c), which rules out the possibility of contributions by congenital mutations in Casp11 (ref. 29) , Nlrp1b 26 or the neighboring gene Gbp1 (ref. 56) to these phenotypes. Such defects also extend to infection with stationaryphase Salmonella typhimurium, known to engage caspase-11 upstream of NLRP3 (refs. 18,34), or L. monocytogenes, which triggers NLRP3 and AIM2 inflammasomes in the canonical pathway 8, 57 . Studies of Gbp5 −/− BMMs have formally excluded cell death induced by logrithmically grown Salmonella typhimurium, which strongly activates the NAIP-NLRC4 inflammasome 34, 58 .
Remarkably, human and mouse GBP5 deficiencies have failed to affect macrophage responses to sterile NLRP3 agents (for example, monosodium urate, alum, and saponin adjuvants such as Q21), a demarcation subsequently seen in multiple studies 12, 18, 22, 23, 59 . Because sterile agents taken up into the endolysosomal network probably engage selective scavenger receptors (such as CD36) 60, 61 , their spatial partitioning might bypass GBP5, which assists assembly of the inflammasome complex mainly in the cytosol 12, 22, 23 . GBP5 activities also seem to lie outside the TAK1-JNK signaling cascade that is initiated upon lysosomal disruption to elicit NLRP3 activation 62 . This partitioning operates in vivo, as Gbp5 −/− mice exhibit pronounced defects in muramyl dipeptide-induced peritonitis but not alum-induced peritonitis and in serum IL-1β plus IL-18 after LPS challenge 12, 22, 23 (Table 1) . They similarly exhibit reduced activity of macrophage and neutrophil caspase-1 in response to microbial triggers but not in response to sterile triggers in situ. Gbp5 −/− mice also have enhanced susceptibility to bacterial infections that require caspase-1 for protection, such as infection with Gram-positive Listeria species and Gram-negative Francisella species 12, 22, 23 . Administration of the caspase-1 inhibitor z-YVAD-FMK renders wild-type mice susceptible to infection with Listeria species but fails to further increase vulnerability in Gbp5 −/− hosts 12 , which confirms the proposal that GBP5 and caspase-1 share the same pathway (Table 1) . Thus, GBP5 acts as a 'rheostat' for inflammasome responses to PAMPs but not to danger-associated molecular patterns in vivo 24 .
The idea of GBPs as regulators of PAMP-sensitive inflammasome responses has grown to include other family members in addition to GBP5 (Fig. 3) . Immunoprecipitation of endogenous GBP5 in 50 and human ASC (PDB accession code 2KN6). Generated with the PV Javascript viewer, from structures deposited in the RCSB database.
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Salmonella species-infected macrophages retrieved GBP2 as a native protein partner (B.-H.K., data not shown), and studies of Gbp2 −/− BMMs have demonstrated a requirement for GBP2 in IL-1β, IL-18 and cell-death responses to this bacterium 18 . GBP2 has also been identified as an important cofactor in AIM2-dependent immunity to F. novicida, along with GBP5 (refs. 22,23) (Fig. 3) . In this scenario, initial detection of bacteria by the DNA sensor cGAS ('cyclic GMP-AMP synthase') and its adaptor STING induce IRF1-dependent expression of GBP2 and GBP5 for interferon-induced intracellular killing and subsequent rounds of DNA release, which then activates the AIM2 inflammasome. Cell-autonomous immunity 63 thus links AIM2-mediated cytokine release to the mobilization of antimicrobial defense mechanisms 22, 23 . These mechanisms seem to manifest n vivo; Gbp2 −/− mice have reduced concentrations of serum IL-18, which is needed for IFN-γ-induced host defense against F. novicida infection 23, 64 . Gbp2 −/− mice are highly susceptible to this bacterium ( Table 1) . GBPs encoded by genes present within a cluster on mouse chromosome 3H1 that contains Gbp2 and Gbp5 are likewise involved in cytokine maturation during infection with Chlamydia trachomatis or C. muridarum 20 . The en bloc removal of this gene cluster (a 173-kilobase deletion of chromosome 3 (Gbp chr3−/− ) 65 ) impairs the release of IL-1β and IL-18 via canonical NLRP3 and AIM2 inflammasomes as well as via the caspase-11-dependent non-canonical pathway (Fig. 3) . GBPs facilitate faster kinetic processing of constitutive IL-18 by NLRP3 inflammasomes after priming with either IFN-γ or LPS, whereas secretion of IL-1β is affected only after stimulation with LPS. These results suggest that TLR-induced NF-κB signaling is important for IL-1β expression but not for IL-18 release by infection with these bacterial species 20 . Multiple GBPs are therefore involved in 'customizing' interferon-induced inflammasome responses to different intracellular bacteria.
GBPs in non-canonical inflammasome activation A major advance in the understanding of bacteria-specific innate immunity has been provided by the identification of caspase-11 (caspase-4 and caspase-5 in humans) as an intracellular LPS receptor that stimulates cytokine secretion via an NLRP3-ASC-caspase-1 complex and pyroptosis through a separate pathway after infection with Gram-negative bacteria 15, [29] [30] [31] [32] . Intact LPS or its acetylated lipid A moiety transfected directly into the cytosol binds the caspase-11 CARD 15, 30, 31 . Cytosolic recognition of LPS bypasses TLR4 signaling and can proceed in a TRIF-independent fashion, although infection by intact Gram-negative bacteria often requires the TLR4-TRIF-IRF3 circuit despite the fact that type I interferons are dispensable for the induction of procaspase-11 itself 14, 34 . Hence, other interferons, principally IFN-γ, and other ISG-encoded factors contribute to non-canonical inflammasome-directed host defense against Gram-negative bacteria. Chief among these ISG-encoded products are the interferon-induced GBPs.
Proteomics-based expression analysis has found substantial upregulation of GBP expression during infection of mouse macrophages with Gram-negative bacteria, and genetic loss-of-function assays have shown the importance pf GBPs for caspase-11-mediated IL-1β secretion and cell death 17, 18, 20 (Fig. 3) . In those studies, GBP defects again most evident were priming with IFN-γ versus LPS or the synthetic RNA duplex poly(I:C), as the first induces more robust GBP expression than the other two stimuli 49, 52 . Nonetheless, if assays are conducted over sufficiently long periods (12-18 hours) to enable
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Interferon-dependent effects have been reported in macrophages infected with S. typhimurium mutants that engage caspase-11, including T3SS ('type III secretion system') mutants (∆SPI-2), flagellin mutants (∆FlhD) and vacuolar mutants (∆SifA) 13, 34 ; SdhA mutants of Legionella pneumophila; and other pathogenic species, including Vibrio cholerae, Shigella flexneri, Citrobacter rodentium, C. trachomatis and C. muridarum 17, 18, 20 . Hence, GBPs are critical for non-canonical inflammasome activation by many Gram-negative bacteria. Gbp2 −/− , Gbp5 −/− and Gbp chr3−/− BMMs primed with IFN-γ are also defective in pyroptosis and IL-1β release following transfection of ultrapure LPS from Escherichia coli or Salmonella or Legionella species 17 (E.-S.P., data not shown) (Fig. 3) . Such impaired responsivity of IFN-γ-activated GBP-deficient cells suggests that GBPs act downstream or independently of phagosomal disruption, since LPS has already been introduced into the cytosol 17 . In unprimed cells, however, responses to transfected LPS seem to be intact, either because GBP expression is too low to affect the outcome or the GBPs operate upstream to disrupt bacterial phagosomes that release lipoglycans for detection 18 . Both mechanisms are plausible, given that GBPs assemble their antibacterial binding partners not only in the cytosol but also on PCVs 12,49 .
Most of the studies discussed above used macrophages from Gbp chr3−/− mice to broadly link GBPs encoded by genes on chromosome 3H1 to the non-canonical pathway 17, 18 . An exciting development has been the application of CRISPR-Cas9 engineering along with conventional gene targeting to individually delete all the GBP-encoding genes in this cluster, to generate single Gbp1 −/− , Gbp2 −/− , Gbp3 −/− , Gbp5 −/− and Gbp7 −/− macrophages 12, 17, 18, 49 (B.-H.K. and C.J.B., data not shown). This has yielded an unexpected result: individual members, such as GBP2, GBP3 and GBP5, each have distinct functions in this pathway. GBP2 binds ASC and GBP5 engages NLRP3 to facilitate assembly of the partner ASC-NLRP3 after heterotypic GBP2-GBP5 interactions (Fig. 3) . This assembly promotes IL-1β secretion following detection of free LPS or LPS-containing microvesicles in the cytosol. In contrast, GBP3 controls pyroptotic elimination of bacteria-infected cells independently of cytokine secretion. Such bifurcating activities evoke a new functional hierarchy in which individual GBPs are responsible for cytokine or cell-death 'decisions' downstream of caspase-11 to promote cell-autonomous immunity to infection with Gramnegative bacteria 63 .
How do the GBPs work?
GBPs affect both canonical inflammasome pathways and non-canonical inflammasome pathways. How do they exert their functions? Part of the answer to this question lies in understanding of their related biochemical and cell-biological properties. At the protein level, human 
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GBPs share 40-98% amino acid identity, with a bidomain architecture composed of an N-terminal GTPase domain and a C-terminal helical domain, the latter harboring 12-13 amphipathic α-helices involved in tail-to-tail dimer contacts 12, 66 . Both the GTPase domain and C-terminal helical domain contribute to homotypic self-assembly, similar to the ~90-kDa dynamin-like GTPases with which they share structural similarities 12, [66] [67] [68] . GBPs typically bind GTP, GDP or GMP with equimolar affinity and exhibit high intrinsic rates of GTPase and GDPase activity (catalytic rate constant, ~100-150/min) due to an internal GTPase-activating protein domain, which obviates the need for external GTPase-activating proteins to accelerate the hydrolysis of GTP or GDP that often aids GBP oligomerization 67, 69 . In addition, some family members (GBP1, GBP2 and GBP5) harbor C-terminal 'CaaX' motifs (where 'aa' indicates two aliphatic residues, and 'X' indicates any amino acid) for isoprenylation and membrane anchorage 70 .
The two properties noted above, guanine nucleotide-dependent self-assembly and membrane binding, are thought to underlie several of their antimicrobial functions. Published studies have shown their dual importance for antibacterial defense through the generation of nucleotide-binding and GTPase-deficient mutants of GBP1 or GBP7 unable to undergo transition-state assembly, as well as GBP1 mutants lacking an intact CaaX motif for lipidation 49 . All such mutants fail to target intracellular Listeria and Mycobacteria species in IFN-γ-activated macrophages with direct loss of cell-autonomous immunity 49, 63 . Similar functional phenotypes have been observed for Toxoplasma gondii in IFN-γ-treated GBP1-mutant mouse macrophages and GBP2-mutant mouse embryonic fibroblasts 71, 72 , while oligomerization mutants (D184N) of human GBP1 interfere with control of C. trachomatis 73 . Co-immunoprecipitation and direct binding studies have revealed that GBPs form homo-and heterotypic complexes with native partners (other GBPs and IRGs, autophagy-related proteins such as Atg4b and p62 (SQSTM1), NADPH oxidase subunits, and inflammasome core proteins), while membrane targeting helps deliver this antimicrobial cargo to PCVs and autolysosomes 12, 49, 65, 70, 74, 75 . GBPmediated delivery of a subset of GKS-containing IRGs is posited to disrupt the parisitophorous vacuole 65 in cells infected with T. gondii, although genes encoding GKS-containing IRGs are missing from the human genome 24 . Thus, other mechanisms probably operate in human cells [76] [77] [78] , especially given the lack of biophysical evidence for human GBPs' having direct dynamin-like 'pinchase' activities that could functionally substitute for the loss of GKS-containing IRGs 24 . Hence, complex assembly rather than vacuolar disruption probably accounts for most of GBPs' inflammasome-related mechanisms, although the latter model could help direct where assembly takes place in the cell or could predominate in specific settings (Fig. 4) .
The first inflammasome-related model proposed for the GBPs arose during their discovery as factors that physically interact with the core machinery 12 . GBP5 binds NLRP3 and facilitates formation of the inflammasome complex through its own self-assembly 12 (Fig. 4) . So far, this remains the only molecular mechanism formally demonstrated and fits the emerging concept of supramolecular organizing centers as important hubs for innate immunity 79 . GBP5 co-immunoprecipitates with native NLRP3 from IFN-γ-activated human monocytes and directly binds the pyrin domain of NLRP3 in cell-free systems to promote the formation of ASC foci 12 . IFN-γ-activated Gbp5 −/− BMMs triggered by NLRP3 stimuli are correspondingly devoid of assembled ASC foci or 'specks' , and reconstitution of GBP-and inflammasomedeficient cells with GBP5 mutants shows that GBP5 tetramerization is essential for the generation of higher-order oligomers of NLRP3-ASC in purified inflammasome complexes 12 . Thus, GBP5 acts as a supramolecular assembly factor for inflammasome activation. In the reconstitution assays reported above, NLRP3-ASC assembly took place without infection; hence, inflammasome activation can occur in the absence of PCV disruption, although assembly may be initiated inside macrophages near PCVs or bacterial outer membrane vesicles that harbor the requisite PAMPs.
In addition to GBP5, tetrameric GBP2 (ref. 80) also binds the core machinery; in this case, it binds ASC to assemble NLRP3 in the noncanonical pathway (B.-H.K., data not shown). Because GBP2 and GBP5 heterotypically interact 70 , each can bring their own inflammasome partner (ASC and NLRP3, respectively) into the final complex to facilitate the processing of caspase-1. This model provides an additional explanation for why GBP2 and GBP5 affect the AIM2-ASC inflammasome 22, 23 : tetramerization of GBP2 induces assembly of its ASC partner, while GBP5-GBP2 multimers might further promote assembly of ASC 'prion-like' structures needed for caspase-1 nucleation and cleavage (Fig. 4) . Whether post-translational lipidation of GBP2 and GBP5 CaaX motifs helps to initiate inflammasome oligomerization directly on endomembranes is unknown. GBP2 also participates in caspase-11-dependent pyroptosis, but GBP5 does not 18 . Here GBP2 is joined by gasdermin D (GSDMD) 21, 81 and a third member of the GBP family, GBP3, as new components of this pathway. Notably, GBP3 does not converge on the core machinery or on PCVs of Salmonella species (B.-H.K., data not shown) (Fig. 4) . Thus, individual GBPs can operate in a non-redundant fashion to confer specific defense activities by engaging different mechanistic partners as shown for GBP1 and GBP7, which assemble p62 (SQSTM1) and NADPH oxidase subunits, respectively, for autophagic and oxidative immunity to intracellular bacteria 49 . These different modes of action also fit the distinct biochemical activities, subcellular localization and pathogen susceptibility profiles of individual GBPs 24, 70, 82 .
The second model proposed for how the GBPs promote inflammasome activation is the disruption of PCVs to release PAMPs for detection by inflammasome sensors 18 ( Fig. 4) . This idea borrows heavily from earlier work on the interferon-induced 21-to 47-kDa GKScontaining IRGs that are able to disrupt T. gondii vacuoles or Chlamydia-containing inclusions in mouse cells but not human cells 55, 65, 72, 78, 83 . GKS-containing IRGs have been linked to membranolytic alterations to PCVs, and an analogous role for GBPs can be inferred from the limited access of antibody to S. typhimurium-containing compartments in Gbp2 −/− or Gbp chr3−/− BMMs via detergent (digitonin)-sensitivity assays, along with the relocation of GBP2 to PCVs for lysis in wild-type cells 18 . This recruitment of GBP2 to S. typhimurium PCVs seems nonspecific, however, since the same antibody to GBP2 (11854-AP-2) detects stationary-phase bacilli in Gbp2 −/− BMMs (B.-H.K., data not shown). Moreover, impaired AIM2 inflammasome responses to F. novicida in Gbp2 −/− , Gbp5 −/− and Gbp chr3−/− BMMs is not accompanied by differences in digitonin permeabilization, which rules out the likelihood of PCV disruption by GBPs in this canonical pathway 23 .
PCV disruption by GBPs might be required for only some vacuolar bacteria and not for others. For example, GBP-dependent inflammasome activation still occurs in macrophages infected with C. muridarum, a chlamydial species that completely blocks the recruitment of GBP2 to the bacterial inclusion as a host-tropic evasion strategy 20 . Conversely, GBP-dependent inflammasome defects are evident in Gbp chr3−/− BMMs treated with purified LPS transfected alone or delivered together with Gram-positive Listeria species that lyse the PCV via their own pore-forming toxin, listeriolysin O, to release LPS into the cytosol 13, 17 . A similar phenotype emerges after infection with Gram-negative S. flexneri, which bypasses host-mediated phagosomal damage altogether, since it escapes via its type III secretion system 17 . Such studies have revealed that the GBPs are still needed even after LPS has reached the cytosol. Finally, trafficking-defective macrophages lacking the GMS-containing IRGM1 (refs. 54,83) and/or IRGM3 (ref. 84) fail to mediate PCV disruption or recruit GBP2 to S. typhimurium and C. trachiomatis PCVs, yet these cells have normal caspase-11 inflammasome responses (B.-H.K., data not shown). So, too, do p62 (SQSTM1)-deficient BMMs that show impaired recruitment of GBP2 to inclusions of Gram-negative bacteria 85, 86 . Hence, PCV disruption is often dispensable for inflammasome activation in both canonical and non-canonical pathways.
Despite such exceptions to the model discussed above, GBP-mediated lysis might still conceivably affect inflammasome mobilization through bacterial damage (bacteriolysis) rather than through vacuolar damage. This alternative mode of action is invoked against F. norvicida to release bacterial DNA for activation of the AIM2 inflammasome 22, 23 (Fig. 4) . Endogenous GBP2 and GBP5 often localize near irregularly shaped F. novica that are permissive to the uptake of propidium iodide, as a measure of decreased membrane integrity and cytosolic exposure. The same bacterial population also appears less frequently in Gbp2 −/− , Gbp5 −/− and Gbp chr3−/− BMMs compared with wild-type cells, and these GBP-knockout BMMs also contain fewer ASC foci 23 . Notably, transfection with the dinucleotide dA:dT or F. norvicida DNA alone activates the inflammasome in a GBPindependent manner, as reported 12, 23 . This result underscores the idea that GBPs must first lyse the bacterial cell envelope to release double-stranded DNA. One important caveat to this interpretation is that ectopic expression of GBP2 and/or GBP5 does not itself reproduce this result 23 . Thus their activities must be indirect and reliant on other interferon-induced proteins to provide the mechanical insult 3 . The identity of such interferon-induced cofactors is currently unknown but remains an important area for future studies.
GBP-mediated immunity and implications for human disease
The predisposition of GBP-deficient mice to infection plus the amelioration of LPS-induced inflammation in human monocytes and mouse macrophages have implications for sepsis, cryopyrin associated periodic syndromes (CAPSs) and autoimmune symptoms with spontaneous interferon production ('interferonopathies'). Septicemia from 
p e r s p e c t I v e
Gram-negative bacteria remains a major problem in intensive care units (causing >250,000 deaths each year in the USA alone) following surgical, burn or infectious trauma 87 . Current therapies that block the initial hyperinflammatory, cytokine-mediated phase improve survival, although patients often enter a protracted immunosuppressive stage that fails to control primary infection or renders them vulnerable to secondary hospital-acquired infections, frequently by opportunistic organisms 87 . Uncoupling systemic inflammation from localized host defense has long been considered one way of slowing the progression of this multifactorial syndrome 88 . The 'rescue' of deactivated monocytes in patients with sepsis through treatment with IFN-γ might aid in their antimicrobial defense 89 . Conceptually, blocking interferoninduced human caspase-4 in monocytes would interfere with both stages 32 ; focusing on downstream targets that separate this bimodal response might therefore be more beneficial. Early blockage of human GBPs involved in cytokine secretion could be followed by manipulation of GBPs involved in pyroptotic clearance of infection as part of a biphasic approach. CAPSs and interferonopathies are two other clinical areas in which GBP-based therapies could be applicable in the future 90, 91 . CAPSs span familial cold autoinflammatory syndrome and Muckle-Wells syndrome, as well as neonatal-onset multisystem inflammatory disorders 90 . These often result from autosomal dominant gain-offunction mutations in NLRP3 that can lead to increased inflammasome assembly and activity. GBP5-specific inhibitors could thus limit CAPS-associated inflammatory sequelae, while congenital GBP5 Cterminal truncations that interfere with self-assembly 66 might act as polygenic contributors to these inflammatory syndromes.
Finally, interferonopathies are type I interferon-dependent inflammatory disorders, including Aicardi-Goutières syndrome, that arise from mutations in genes encoding nucleic acid sensors that cause elevated or inappropriate interferon production (for example, TREX1, SAMHD1, RNASEH2A, ADAR and IFIH1) 91 . These disorders, together with gain-of-function mutations in the gene encoding STING (TMEM173) that are associated with systemic lupus erythematosus 92 , might arise partly because GBP-dependent inflammasome responses are activated by increased amounts of type I interferon. Again, therapeutic agents that target these inflammasome-related GBPs (GBP2, GBP3 and GBP5) might serve as possible avenues for treatment in the future.
Concluding remarks
The past 5 years have witnessed a 'cavalcade' of discoveries about the activity of interferon-inducible GBPs during antibacterial host defense and inflammasome activation 3, 24 . GBPs operate against at least ten bacterial species that trigger canonical or non-canonical inflammasome responses to control the secretion of IL-1β plus IL-18 and pyroptosis 12, 17, 18, 22, 23 . Allelic deletions such as those in Gbp1 −/− , Gbp2 −/− , Gbp3 −/− , Gbp5 −/− , Gbp7 −/− and Gbp chr3−/− mice or macrophages often yield profound susceptibility or inflammatory phenotypes, as do GBP-defective human cells 12, 17, 18, 22, 23, 49, 59, 65, [71] [72] [73] 79 . The latter remains an understudied area with important consequences for disease. Because clues to the inflammasome-related activities of GBPs first arose from broad evolutionary analysis 12 , 'mining' the fossil record should continue to yield insights about how interferon-induced GBPs mobilize protective immunity across the animal kingdom. p e r s p e c t I v e nature immunology VOLUME 17 NUMBER 5 MAY 2016
